Disease
|
Drug/Important Bio-Agent (IBA)
2 | InflammasomesIBA
03/2022
-
01/2021 |
2 | Contrast MediaIBA
01/2022
-
10/2019 |
1 | HMGB1 Protein (HMG1)IBA
03/2022 |
1 | Eosine Yellowish-(YS) (Eosin)IBA
03/2022 |
1 | ferric oxide (iron oxide)IBA
01/2022 |
1 | dysprosium oxide (dysprosia)IBA
01/2022 |
1 | CadmiumIBA
01/2022 |
1 | VaccinesIBA
01/2022 |
1 | Hazardous Substances (Hazardous Materials)IBA
01/2022 |
1 | N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA
01/2021 |
1 | CopperIBA
01/2021 |
1 | Interleukin-18 (Interleukin 18)IBA
01/2021 |
1 | GadoliniumIBA
10/2019 |
1 | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
10/2019 |
1 | Biological ProductsIBA
01/2019 |
1 | ThrombospondinsIBA
01/2019 |
1 | DisintegrinsIBA
01/2019 |
1 | Amyloid (Amyloid Fibrils)IBA
01/2019 |
1 | Metalloproteases (Metalloproteinases)IBA
01/2019 |
|
Therapy/Procedure
|